Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Cash Flows (Unaudited)

v3.23.2
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Cash Flows From Operating Activities    
Net income (loss) $ 526 $ (6,186)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:    
Depreciation and amortization 714 1,571
Interest accretion expense 66 85
Amortization of deferred financing fees 28 31
Stock-based compensation 349 613
ESPP expense 46
Change in fair value of note payable 142 (160)
Mark to market on warrants (68)
Change in fair value of contingent consideration (311)
Other changes in operating assets and liabilities:    
Accounts receivable (497) (288)
Other current assets (101) (3)
Operating lease right of use assets 349 549
Accounts payable 610 794
Accrued salaries and bonus (329) 278
Other accrued expenses (138) (654)
Operating lease liabilities (337) (541)
Other long-term liabilities 162 72
Net cash provided by (used in) operating activities 1,544 (4,172)
Cash Flows From Investing Activity    
Working capital adjustment on sale of Interpace Pharma Solutions (117)
Purchase of property and equipment (176) (86)
Net cash used in investing activities (293) (86)
Cash Flows From Financing Activities    
Issuance of common stock, net of expenses 59
Proceeds from convertible debt 2,000
(Payments) borrowings on line of credit (1,000) 1,000
Net cash (used in) provided by financing activities (1,000) 3,059
Net increase (decrease) in cash, cash equivalents and restricted cash 251 (1,199)
Cash, cash equivalents and restricted cash from continuing operations– beginning 4,828 2,922
Cash, cash equivalents and restricted cash from discontinued operations– beginning 392
Cash, cash equivalents and restricted cash – beginning 4,828 3,314
Cash, cash equivalents and restricted cash from continuing operations– ending 5,079 1,943
Cash, cash equivalents and restricted cash from discontinued operations– ending 172
Cash, cash equivalents and restricted cash – ending $ 5,079 $ 2,115